RxDoctor Payments Data

Amber Mason, NP

Nurse Practitioner · Cedar Knolls, NJNPI 1689183675

Payments from drug & device makers

$655in general payments, 2019–2025

Across 36 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$155
  • AbbVie$148
  • Pfizer$104
  • GSK$60
  • Amgen$58
  • Novo Nordisk$48
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$655100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott2$155
AbbVie11$148
Pfizer7$104
GSK4$60
Amgen4$58
Novo Nordisk3$48
Corcept Therapeutics1$22
Acadia Pharmaceuticals Inc1$17
Althera Pharmaceuticals LLC1$16
Merck1$15
Irhythm Technologies, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$655 in reported general payments places this provider in the 75th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$26,990
Medicare patients
126
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$169,945
XareltoRivaroxaban69$69,745
EntrestoSacubitril/Valsartan28$28,965
Repatha SureclickEvolocumab45$27,826
JanuviaSitagliptin Phosphate17$23,920
JardianceEmpagliflozin13$19,479
VascepaIcosapent Ethyl11$9,217
Colesevelam Hcl13$7,076
ZetiaEzetimibe11$4,242
Atorvastatin Calcium409$4,051
Valsartan73$3,719
Rosuvastatin Calcium237$3,600
Metoprolol Succinate249$3,057
Ranolazine ErRanolazine15$2,464
Midodrine Hcl22$1,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$169,945138 claims
MerckJanuvia$15$23,92017 claims
AbbVieSynthroid$148$1,32824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Cedar Knolls

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →